Cargando…

Benzo[g]quinazolines as antifungal against candidiasis: Screening, molecular docking, and QSAR investigations

Candida albicans, an opportunistic pathogen, is the most common type of fungus and represents a substantial source of human invasive disease (nosocomial infection). This category of fungi are part of our microbiota, and given the appropriate environmental conditions, it has the potential to cause bo...

Descripción completa

Detalles Bibliográficos
Autores principales: Abuelizz, Hatem A., Bakheit, Ahmed H., Al-Agamy, Mohamed H., Rashid, Harunor, Mostafa, Gamal A.E., Al-Salahi, Rashad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10203769/
https://www.ncbi.nlm.nih.gov/pubmed/37228321
http://dx.doi.org/10.1016/j.jsps.2023.04.012
_version_ 1785045702531874816
author Abuelizz, Hatem A.
Bakheit, Ahmed H.
Al-Agamy, Mohamed H.
Rashid, Harunor
Mostafa, Gamal A.E.
Al-Salahi, Rashad
author_facet Abuelizz, Hatem A.
Bakheit, Ahmed H.
Al-Agamy, Mohamed H.
Rashid, Harunor
Mostafa, Gamal A.E.
Al-Salahi, Rashad
author_sort Abuelizz, Hatem A.
collection PubMed
description Candida albicans, an opportunistic pathogen, is the most common type of fungus and represents a substantial source of human invasive disease (nosocomial infection). This category of fungi are part of our microbiota, and given the appropriate environmental conditions, it has the potential to cause both superficial and systemic infections. There is a soaring resistance against the available anticandidal agents. The purpose of this research is to investigate the activity of certain previously synthesized benzo[g]quinazolines against C. albicans in vitro by using the cup-plate diffusion method. There was a marked difference in the effectiveness of the target compounds 1–6 against the sample of C. albicans that was tested. Benzo[g]quinazolines 1 (inhibition zone = 20 mm) and 2 (inhibition zone = 22 mm) had good effects in comparison to fluconazole (inhibition zone = 26 mm). A docking study was conducted between benzo[g]quinazolines 1–6 and Candida spp. CYP51 to establish the binding mode compared with fluconazole and VT-1161 (oteseconazole) as reference medicines, and it was determined that binding at the active site of Candida spp. CYP51 occurred in the same manner. Quantitative structure–activity relationship (QSAR) investigation was performed to further characterize the identified anticandidal agents and recognize the major regulatory components governing such activity. In future studies, the benzo[g]quinazoline scaffold could serve as a model for the design and development of novel derivatives with antifungal potential.
format Online
Article
Text
id pubmed-10203769
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-102037692023-05-24 Benzo[g]quinazolines as antifungal against candidiasis: Screening, molecular docking, and QSAR investigations Abuelizz, Hatem A. Bakheit, Ahmed H. Al-Agamy, Mohamed H. Rashid, Harunor Mostafa, Gamal A.E. Al-Salahi, Rashad Saudi Pharm J Original Article Candida albicans, an opportunistic pathogen, is the most common type of fungus and represents a substantial source of human invasive disease (nosocomial infection). This category of fungi are part of our microbiota, and given the appropriate environmental conditions, it has the potential to cause both superficial and systemic infections. There is a soaring resistance against the available anticandidal agents. The purpose of this research is to investigate the activity of certain previously synthesized benzo[g]quinazolines against C. albicans in vitro by using the cup-plate diffusion method. There was a marked difference in the effectiveness of the target compounds 1–6 against the sample of C. albicans that was tested. Benzo[g]quinazolines 1 (inhibition zone = 20 mm) and 2 (inhibition zone = 22 mm) had good effects in comparison to fluconazole (inhibition zone = 26 mm). A docking study was conducted between benzo[g]quinazolines 1–6 and Candida spp. CYP51 to establish the binding mode compared with fluconazole and VT-1161 (oteseconazole) as reference medicines, and it was determined that binding at the active site of Candida spp. CYP51 occurred in the same manner. Quantitative structure–activity relationship (QSAR) investigation was performed to further characterize the identified anticandidal agents and recognize the major regulatory components governing such activity. In future studies, the benzo[g]quinazoline scaffold could serve as a model for the design and development of novel derivatives with antifungal potential. Elsevier 2023-06 2023-04-15 /pmc/articles/PMC10203769/ /pubmed/37228321 http://dx.doi.org/10.1016/j.jsps.2023.04.012 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Abuelizz, Hatem A.
Bakheit, Ahmed H.
Al-Agamy, Mohamed H.
Rashid, Harunor
Mostafa, Gamal A.E.
Al-Salahi, Rashad
Benzo[g]quinazolines as antifungal against candidiasis: Screening, molecular docking, and QSAR investigations
title Benzo[g]quinazolines as antifungal against candidiasis: Screening, molecular docking, and QSAR investigations
title_full Benzo[g]quinazolines as antifungal against candidiasis: Screening, molecular docking, and QSAR investigations
title_fullStr Benzo[g]quinazolines as antifungal against candidiasis: Screening, molecular docking, and QSAR investigations
title_full_unstemmed Benzo[g]quinazolines as antifungal against candidiasis: Screening, molecular docking, and QSAR investigations
title_short Benzo[g]quinazolines as antifungal against candidiasis: Screening, molecular docking, and QSAR investigations
title_sort benzo[g]quinazolines as antifungal against candidiasis: screening, molecular docking, and qsar investigations
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10203769/
https://www.ncbi.nlm.nih.gov/pubmed/37228321
http://dx.doi.org/10.1016/j.jsps.2023.04.012
work_keys_str_mv AT abuelizzhatema benzogquinazolinesasantifungalagainstcandidiasisscreeningmoleculardockingandqsarinvestigations
AT bakheitahmedh benzogquinazolinesasantifungalagainstcandidiasisscreeningmoleculardockingandqsarinvestigations
AT alagamymohamedh benzogquinazolinesasantifungalagainstcandidiasisscreeningmoleculardockingandqsarinvestigations
AT rashidharunor benzogquinazolinesasantifungalagainstcandidiasisscreeningmoleculardockingandqsarinvestigations
AT mostafagamalae benzogquinazolinesasantifungalagainstcandidiasisscreeningmoleculardockingandqsarinvestigations
AT alsalahirashad benzogquinazolinesasantifungalagainstcandidiasisscreeningmoleculardockingandqsarinvestigations